A Randomized Double-Blind Placebo-Controlled Trial of efficacy of phloroglucinol in Irritable Bowel Syndrome
- Conditions
- Diseases of the digestive system
- Registration Number
- KCT0000494
- Lead Sponsor
- Chung-Ang Univerisity Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 72
1) The patients with diarrhea-dominant IBS (D-IBS) consented by ROME III.
2) The patients who had no organic bowel disease in the colonoscopy or Ba-enema performed within 5 years.
3) The patients who consented this trial.
1) The patients who were allergic to fluoroglucin.
2) The patients who received abdominal operation except appendectomy and hernioplasty
3) The patients who have the diseases that might affect the assessment of drug efficacy, such as IBD and colon cancer.
4) The patients who take medication that might affect the assessment of drug efficacy, such as IBD and colon cancer.
5) The patients with glaucoma or prostate hypertrophy
6) The patients who have severe medical disease, such as liver cirrhosis, congestive heart failure, and chronic renal failure.
7) Prangnant or lactating patients
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Subject global assessment(SGA)
- Secondary Outcome Measures
Name Time Method visual analogue scale (VAS);Bristol Stool Scale;IBS-QOL(quality of life) questionnaire;Hospital Anxiety and Depression Scale;Adverse Drug Reactions;ADRs